2,3-二氢苯并[b][1,4]二恶英-6-羧酸乙酯 | 20825-87-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 中文名称: 2,3-二氢苯并[b][1,4]二恶英-6-羧酸乙酯
• 中文别名: 苯并二氧六环-6-羧酸
• 英文名称: ethyl 2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylate
• 英文别名: 2,3-dihydrobenzo[1,4]dioxine-6-carboxylic acid ethyl ester；ethyl 2,3-dihydro-1,4-benzodioxin-6-carboxylate；2,3-dihydro-benzo[1,4]dioxin-6-carboxylic acid ethyl ester；2,3-Dihydro-benzo[1,4]dioxin-6-carbonsaeure-aethylester；ethyl 2,3-dihydro-1,4-benzodioxine-6-carboxylate
• CAS: 20825-87-0
• 化学式: C₁₁H₁₂O₄
• mdl: MFCD06204332
• 分子量: 208.214
• InChiKey: LIQWCKWRILLHAQ-UHFFFAOYSA-N

物化性质

• 沸点：
  307.1±21.0 °C(Predicted)
• 密度：
  1.205±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  2,3-二氢苯并[b][1,4]二恶英-6-羧酸乙酯 在 sodium ethanolate 、 一水合肼 、 potassium hydroxide 作用下， 以 乙醇 为溶剂， 生成 2-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-5-((2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)thio)-1,3,4-oxadiazole
  参考文献：
  名称：

  Novel 1,3,4-oxadiazole thioether derivatives targeting thymidylate synthase as dual anticancer/antimicrobial agents

  摘要：

  A series of novel 1,3,4-oxadiazole thioether derivatives (compounds 9-44) were designed and synthesized as potential inhibitors of thymidylate synthase (TS) and as anticancer agents. The in vitro anticancer activities of these compounds were evaluated against three cancer cell lines by the MTT method. Among all the designed compounds, compound 18 bearing a nitro substituent exhibited more potent in vitro anticancer activities with IC50 values of 0.7 +/- 0.2, 30.0 +/- 1.2, 18.3 +/- 1.4 mu M, respectively, which was superior to the positive control. In the further study, it was identified as the most potent inhibitor against two kinds of TS protein (for human TS and Escherichia coli TS, IC50 values: 0.62 and 0.47 mu M, respectively) in the TS inhibition assay in vitro and the most potent antibacterial agents with MIC (minimum inhibitory concentrations) of 1.56-3.13 mu g/mL against the tested four bacterial strains. Molecular docking and 3D-QSAR study supported that compound 18 can be selected as dual antitumor/antibacterial candidate in the future study. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.02.008
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 盐酸 、 乙醇 作用下， 生成 2,3-二氢苯并[b][1,4]二恶英-6-羧酸乙酯
  参考文献：
  名称：

  Fittig; Macalpine, Justus Liebigs Annalen der Chemie, 1873, vol. 168, p. 112

  摘要：

  DOI：

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Synthesis and Antibacterial Activity of Cinnamaldehyde Acylhydrazone with a 1,4-Benzodioxan Fragment as a Novel Class of Potent β-Ketoacyl–Acyl Carrier Protein Synthase III (FabH) Inhibitor
  作者：Xiaoda Song、Yushun Yang、Jing Zhao、Yangjian Chen

  DOI：10.1248/cpb.c14-00485

  日期：——

  Fatty acid biosynthesis is essential for bacterial survival. β-Ketoacyl–acyl carrier protein (ACP) synthase III (FabH), is a particularly attractive antibacterial target, since it is central to the initiation of fatty acid biosynthesis. Three series of 21 cinnamaldehyde acylhydrazone derivatives, A3–9, B3–9, and C3–9, were synthesized and evaluated for FabH-inhibitory activity. Compound B6 showed the most potent biological activity against Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Bacillus subtilis (minimum inhibitory concentrations (MICs) values: 1.56–3.13 µg/mL) and was comparable with the positive control. Docking simulation by positioning compound B6 in the FabH structure active site was performed to explore the possible binding model.

  脂肪酸生物合成对细菌的生存至关重要。β-酮酰基载体蛋白（ACP）合成酶III（FabH）因其在脂肪酸生物合成启动中的核心作用，是一个特别有吸引力的抗菌目标。合成了三系列共21种肉桂醛酰腙衍生物A3-9、B3-9和C3-9，并评估了它们对FabH的抑制活性。化合物B6显示出对大肠杆菌、绿脓杆菌、金黄色葡萄球菌和枯草芽孢杆菌最强的生物活性（最低抑制浓度（MICs）值为1.56-3.13 µg/mL），与阳性对照相当。通过将化合物B6定位在FabH结构活性位点的对接模拟，探索了可能的结合模型。
• Design, modification and 3D QSAR studies of novel 2,3-dihydrobenzo[b][1,4]dioxin-containing 4,5-dihydro-1H-pyrazole derivatives as inhibitors of B-Raf kinase
  作者：Yu-Shun Yang、Qing-Shan Li、Shuai Sun、Yan-Bin Zhang、Xiao-Liang Wang、Fei Zhang、Jian-Feng Tang、Hai-Liang Zhu

  DOI：10.1016/j.bmc.2012.08.043

  日期：2012.10

  Two series of novel 2,3-dihydrobenzo[b][1,4]dioxin-containing 4,5-dihydro-1H-pyrazole derivatives C1–C15 and D1–D15 have been synthesized and evaluated for their B-Raf inhibitory and anti-proliferation activities. Compound C14 ((3-(4-bromophenyl)-5-(2-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methanone) showed the most potent biological activity against B-RafV600E

  合成了两个系列的新型含2,3-二氢苯并[ b ] [1,4]二恶英的4,5-二氢-1 H-吡唑衍生物C1 - C15和D1 - D15，并评估了它们对B-Raf的抑制作用和防扩散活动。化合物C14（（3-（4-溴苯基）-5-（2-氟苯基）-4,5-二氢-1 H-吡唑-1-基）（2,3-二氢苯并[ b ] [1,4]二恶英-6-yl）methanone）对B-Raf V600E（IC 50  = 0.11μM）和WM266.4人黑素瘤细胞系（GI 50 = 0.58μM），与阳性对照厄洛替尼相当，并且比我们以前最好的化合物更有效，而D10（（2,3-dihydrobenzo [ b ] [1,4] dioxin-2-yl）（5-（3-氟苯基）-3-苯基-4,5-二氢-1 H-吡唑-1-基）甲酮在D系列中表现最好（IC 50  = 1.70μM; GI 50  = 1.45μM）。进行了对接模
• Modulators of ATP-binding cassette transporters
  申请人：Hadida Ruah S. Sara

  公开号：US20070244159A1

  公开（公告）日：2007-10-18

  Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药学上可接受的组合物，可用作调节ATP结合盒（“ABC”）转运蛋白或其片段的工具，包括囊性纤维化跨膜传导调节蛋白（“CFTR”）。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导的疾病的方法。